4-Methylpiperidine → 4-(2,6-Diethyl-1,1-dioxo-1lambda6-[1,2,6]thiadiazinan-4-yl)-2-(4-methyl-piperidin-1-yl)-phenylamine

HRID 1008935Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1008935
C(OC(=O)[NH:7][C:8]1[CH:13]=[CH:12][C:11]([CH:14]2[CH2:19][N:18]([CH2:20][CH3:21])[S:17](=[O:23])(=[O:22])[N:16]([CH2:24][CH3:25])[CH2:15]2)=[CH:10][C:9]=1Br)(C)(C)C.[CH3:28][CH:29]1[CH2:34][CH2:33][NH:32][CH2:31][CH2:30]1>>[CH2:24]([N:16]1[CH2:15][CH:14]([C:11]2[CH:12]=[CH:13][C:8]([NH2:7])=[C:9]([N:32]3[CH2:33][CH2:34][CH:29]([CH3:28])[CH2:30][CH2:31]3)[CH:10]=2)[CH2:19][N:18]([CH2:20][CH3:21])[S:17]1(=[O:23])=[O:22])[CH3:25]

Komponenten

3

Edukt 2

HCID 693814-MethylpiperidineHCID 59771222[2-Bromo-4-(2,6-diethyl-1,1-dioxo-1lambda6-[1,2,6]thiadiazinan-4-yl)-phenyl]-carbamic acid tert-butyl ester

Produkt 1

HCID 597711574-(2,6-Diethyl-1,1-dioxo-1lambda6-[1,2,6]thiadiazinan-4-yl)-2-(4-methyl-piperidin-1-yl)-phenylamine

Versuchsvorschrift

The title compound is prepared from [2-bromo-4-(2,6-diethyl-1,1-dioxo-1λ6-[1,2,6]thiadiazinan-4-yl)-phenyl]-carbamic acid tert-butyl ester (as prepared in the previous step) and 4-methylpiperidine following the literature procedure of Buchwald (Org. Lett., 4, 2885-8 (2002)). The residue obtained is purified by silica gel chromatography with an appropriate solvent mixture. After isolation, removal of the BOC protecting group from the resulting intermediate is carried out by stirring at RT in TFA-DCM (1:2), monitoring by TLC for completion, and then concentration in vacuo.

Aufarbeitung

  1. customThe residue obtained
  2. customis purified by silica gel chromatography with an appropriate solvent mixture
  3. customAfter isolation, removal of the BOC protecting group from the resulting intermediate
  4. concentrationconcentration in vacuo

Quellen und Nachweise

ORD-Eintrag
ord-0aee0b2769704ad7b0ea45ccd415cb38
Quelldatensatz
uspto-grants-2011_07
Patentnummer
US07973035B2

Notizen zur Reaktion

Wird geladen…